For example gastric cancer with growing TP53/ERBB2 mutated clone will benefit of Transtuzumab plus chemotherapy.21 Breast cancer with CCND1/FGFR1 mutated clone will benefit of combined erdafitinib plus ribociclib and fulvestrant.22 Here, ERBB2 is linked to breast cancer.